Biomarker

生物标志物

• 批准号: 10262853
• 负责人: CHRISTOPHER T WHITLOW
• 金额: $ 78.53万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10262853
• 关键词: Acetoacetates; Address; Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease model; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid beta-Protein; Animal Model; Animals; Area; Biological; Biological Markers; Biometry; Blood; Blood Vessels; Brain; Brain imaging; Cerebrovascular Disorders; Classification; Clinical; Clinical Data; Clinical assessments; Cognition; Collection; Communities; Complement; Consensus; Consultations; Cyclotrons; Data; Data Management Resources; Data Set; Dementia; Development; Disease; Disease Progression; Doctor of Philosophy; Enrollment; Frequencies; Future; Genomics; Head; Image; Impaired cognition; Individual; Infrastructure; Ligands; Magnetic Resonance Imaging; Measures; Metabolic; Methods; Microtubules; Mission; Mitochondria; Nature; Neurodegenerative Disorders; Participant; Pathologic; Pathology; Persons; Phenotype; Positron-Emission Tomography; Prevention strategy; Process; Production; Protocols documentation; Research; Research Personnel; Resolution; Resources; Risk; Rodent Model; Role; Scientific Advances and Accomplishments; Slice; Spin Labels; Spinal Puncture; Standardization; Structure; Synaptic Vesicles; Systems Analysis; Techniques; Therapeutic Intervention; Tracer; Training; Translational Research; Underrepresented Populations; Vascular Diseases; adjudication; advanced analytics; age related; amyloid pathology; base; brain health; cerebrovascular; clinical biomarkers; cohort; data management; data sharing; ethnic diversity; experience; forest; health disparity; imaging biomarker; imaging modality; imaging program; innovation; lifestyle factors; medical schools; member; mild cognitive impairment; molecular imaging; multimodality; neuroimaging; neuropathology; next generation; nonhuman primate; normal aging; novel; novel strategies; racial and ethnic; racial diversity; radiotracer; ranpirnase; relational database; serial imaging; targeted treatment; tau Proteins; treatment response; user-friendly; vascular risk factor

Imaging Biomarker Core – Project Summary The Imaging Biomarker Core (IBC) of the Alzheimer’s Disease Research Center (ADRC) at Wake Forest School of Medicine will address a critical need to establish biomarkers that reliably differentiate Alzheimer’s disease (AD) from other conditions that affect cognition in aging. Recently, an AD research framework was developed for a biologically-based classification to enhance identification of disease mechanisms, to appropriately target therapeutic interventions, and to track therapeutic response and disease progression. Neuroimaging techniques, such as magnetic resonance imaging (MRI) to measure structural changes and positron emission tomography (PET) to track changes in pathological hallmarks such as beta-amyloid and tau, comprise a powerful approach to characterize the progressive pathology associated with cognitive decline and to differentiate AD from other dementias. To establish reliable biomarkers associated with AD and other conditions that impair cognition with aging will require a large collaborative effort and the national ADRC network is ideally suited to address this need. The Wake Forest ADRC can make unique contributions to the network. The IBC will conduct longitudinal, multimodal neuroimaging paired with phenotypic and genomic characterization of a diverse cohort of participants. The IBC will provide expertise and resources to complement the ADRC’s themes that focus on: 1) early transitions from normal aging to mild cognitive impairment (MCI) and AD; 2) the role of metabolic and vascular risk in these transitions; and 3) the nature of these relationships in persons from underrepresented groups (URGs). The first aim of the IBC will be to leverage the Clinical Core and extensive existing Wake Forest imaging infrastructure, including research- dedicated PET and MRI, cyclotron, and advanced analytic pipelines, to conduct state-of-the-art longitudinal imaging to help identify the causes of AD and develop novel strategies for prevention and treatment. As a second aim, the IBC will integrate imaging data with clinical, biomarker, and other research data to facilitate scientific discovery. The third aim will be to develop imaging methods for animal models of AD, and the final aim will be to provide training and consultation on the latest scientific advances in neuroimaging to ADRC- affiliated investigators and trainees. Through these aims, the Wake Forest ADRC IBC will further the understanding of AD pathology and its relationship to cognitive decline and will significantly enhance the Center’s contribution to the ADRC network and to investigators worldwide.

成像生物标志物核心-项目总结 维克森林阿尔茨海默病研究中心（ADRC）的成像生物标志物核心（IBC） 医学院将解决建立可靠区分阿尔茨海默氏症的生物标志物的迫切需要 疾病（AD）与其他影响衰老认知的疾病之间的关系。最近，一个AD研究框架 开发用于基于生物学的分类，以增强疾病机制的识别， 适当地靶向治疗干预，并跟踪治疗反应和疾病进展。 神经成像技术，如磁共振成像（MRI），以测量结构变化， 正电子发射断层扫描（PET）来跟踪病理标志如β-淀粉样蛋白和tau蛋白的变化， 包括表征与认知衰退相关的进行性病理学的强有力的方法， 来区分AD和其他痴呆建立与AD和其他疾病相关的可靠生物标志物 随着年龄的增长而损害认知的条件将需要大量的合作努力和国家ADRC 网络非常适合满足这一需求。维克森林ADRC可以为 网络IBC将进行纵向、多模式神经成像， 对不同参与者群体的特征描述。IBC将提供专业知识和资源， 补充ADRC的主题，重点是：1）从正常老化到轻度认知的早期过渡 2）代谢和血管风险在这些转变中的作用;以及3） 这些关系的人来自代表性不足的群体（URG）。国际生物伦理委员会的首要目标是 利用临床核心和广泛的现有维克森林成像基础设施，包括研究- 专用的PET和MRI、回旋加速器和先进的分析管道， 影像学有助于确定AD的病因，并制定新的预防和治疗策略。作为 第二个目标是，IBC将把成像数据与临床、生物标志物和其他研究数据相结合， 科学发现第三个目标将是开发AD动物模型的成像方法，最后一个目标将是开发AD动物模型的成像方法。 目的是为ADRC提供有关神经影像学最新科学进展的培训和咨询- 附属调查员和实习生。通过这些目标，维克森林ADRC IBC将进一步 了解AD病理学及其与认知能力下降的关系，将显著提高 中心对ADRC网络和全球调查人员的贡献。